Treatment of huntington disease with a cholinergic agonist

John G. Nutt, Arnold Rosin, Thomas N. Chase

Research output: Contribution to journalArticle

33 Scopus citations


The involuntary movements of Huntington disease may be related to cholinergic hypofunction in the striatum. For this reason, the effect of a direct cholinergic agonist, arecoline, was studied in six patients with this disorder. Rather than improving the chorea, arecoline tended to exacerbate the choreic movements. Arecoline did produce significant alterations of blood pressure, heart rate, and body temperature, probably by central cholinergic stimulation.

Original languageEnglish (US)
Pages (from-to)1061-1064
Number of pages4
Issue number10
StatePublished - Oct 1978


ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Nutt, J. G., Rosin, A., & Chase, T. N. (1978). Treatment of huntington disease with a cholinergic agonist. Neurology, 28(10), 1061-1064.